Analyst Price Target is $52.84
▼ -5.96% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for UCB in the last 3 months. The average price target is $52.84, with a high forecast of $52.84 and a low forecast of $52.84. The average price target represents a -5.96% upside from the last price of $56.19.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in UCB. This Buy consensus rating has held steady for over two years.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.